Wallner; Barbara P.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wallner; Barbara P..The latest application filed is for "epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof".

Company Profile

0.27.16

Wallner; Barbara P. - Cohasset MA
Wallner; Barbara P. - Weston MA
Wallner; Barbara P. - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Epichaperome Inhibitor Therapy For Traumatic Brain Injury And Sequelae Thereof App 20210161902 - Wallner; Barbara P.	2021-06-03
Method for controlling angiogenesis in animals Grant 8,796,329 - Wallner , et al. August 5, 2	2014-08-05
Indibulin Therapy App 20140193519 - Wallner; Barbara P. ; et al.	2014-07-10
Salts of isophosphoramide mustard and analogs thereof Grant 8,604,007 - Amedio, Jr. , et al. December 10, 2	2013-12-10
Indibulin Therapy App 20130084345 - Wallner; Barbara P. ; et al.	2013-04-04
Combination Therapy With Organic Arsenicals App 20120295861 - WALLNER; Barbara P. ; et al.	2012-11-22
Combination therapy with organic arsenicals Grant 8,252,773 - Wallner , et al. August 28, 2	2012-08-28
Combination Therapy With Organic Arsenicals App 20100311689 - Wallner; Barbara P. ; et al.	2010-12-09
Salts of isophosphoramide mustard and analogs thereof App 20080255056 - Amedio; John C. ; et al.	2008-10-16
Indibulin therapy App 20080241274 - Wallner; Barbara P. ; et al.	2008-10-02
Anti-tumor Agents App 20080221068 - Wallner; Barbara P. ; et al.	2008-09-11
Method for controlling angiogenesis in animals App 20080139629 - Wallner; Barbara P. ; et al.	2008-06-12
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction Grant 7,323,171 - Wallner , et al. January 29, 2	2008-01-29
Anti-tumor agents Grant 7,282,484 - Wallner , et al. October 16, 2	2007-10-16
Stimulation of hematopoietic cells in vitro Grant 7,276,371 - Bachovchin , et al. October 2, 2	2007-10-02
Regulation of substrate activity Grant 7,265,118 - Wallner September 4, 2	2007-09-04
Anti-tumor agents Grant 7,259,138 - Wallner , et al. August 21, 2	2007-08-21
Hematopoietic stimulation App 20070135354 - Wallner; Barbara P. ; et al.	2007-06-14
Hematopoietic stimulation Grant 7,067,489 - Wallner , et al. June 27, 2	2006-06-27
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction App 20060084107 - Wallner; Barbara P. ; et al.	2006-04-20
Regulation of substrate activity App 20060052310 - Wallner; Barbara P.	2006-03-09
Regulation of substrate activity Grant 6,979,697 - Wallner December 27, 2	2005-12-27
Anti-tumor agents Grant 6,890,904 - Wallner , et al. May 10, 2	2005-05-10
Hematopoietic stimulation App 20050037976 - Wallner, Barbara P. ; et al.	2005-02-17
Hematopoietic stimulation Grant 6,770,628 - Wallner , et al. August 3, 2	2004-08-03
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction Grant 6,764,681 - Wallner , et al. July 20, 2	2004-07-20
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction App 20040136987 - Wallner, Barbara P. ; et al.	2004-07-15
Cyclic boroproline compounds Grant 6,355,614 - Wallner March 12, 2	2002-03-12
Hematopoietic stimulation App 20020013279 - Wallner, Barbara P. ; et al.	2002-01-31
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction App 20020009449 - Wallner, Barbara P. ; et al.	2002-01-24
Hematopoietic stimulation Grant 6,300,314 - Wallner , et al. October 9, 2	2001-10-09
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction Grant 6,162,432 - Wallner , et al. December 19, 2	2000-12-19
Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation Grant 5,928,643 - Wallner , et al. July 27, 1	1999-07-27
CD2-binding domain of lymphocyte function associated antigen-3 Grant 5,914,111 - Wallner , et al. June 22, 1	1999-06-22
Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3 Grant 5,728,677 - Wallner , et al. March 17, 1	1998-03-17
CD2-binding domain of lymphocyte function associated antigen 3 Grant 5,547,853 - Wallner , et al. August 20, 1	1996-08-20
Recombinant DNA molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence Grant 5,223,394 - Wallner June 29, 1	1993-06-29
DNA sequences, recombinant DNA molecules and processes for producing PI-linked lymphocyte function associated antigen-3 Grant 5,185,441 - Wallner , et al. February 9, 1	1993-02-09
DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides Grant 5,081,019 - Wallner , et al. January 14, 1	1992-01-14
DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 Grant 4,956,281 - Wallner , et al. September 11, 1	1990-09-11
DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides Grant 4,879,224 - Wallner , et al. November 7, 1	1989-11-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.